{
    "nct_id": "NCT02998528",
    "official_title": "Randomized, OpenLabel, Phase 3 Trial of Nivolumab Plus Ipilimumab or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Early Stage NSCLC",
    "inclusion_criteria": "* Early stage IB-IIIA, operable non-small cell lung cancer, confirmed in tissue\n* Lung function capacity capable of tolerating the proposed lung surgery\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1\n* Available tissue of primary lung tumor\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Presence of locally advanced, inoperable or metastatic disease\n* Participants with active, known or suspected autoimmune disease\n* Prior treatment with any drug that targets T cell co-stimulations pathways (such as checkpoint inhibitors)\n\nOther protocol defined inclusion/exclusion criteria apply",
    "miscellaneous_criteria": ""
}